Drug
Dordaviprone (ONC201)
Dordaviprone (ONC201) is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/4)
Active Trials
1(20%)
Terminated
4(80%)
Phase Distribution
Ph phase_1
1
20%
Ph phase_3
1
20%
Ph phase_2
3
60%
Phase Distribution
1
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 4 finished
Non-Completion Rate
100.0%
4 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Terminated(4)
Detailed Status
Terminated4
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
0.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)
Trials by Status
terminated480%
recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
recruitingphase_3
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562
terminatedphase_2
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
NCT03295396
terminatedphase_1
ONC201 in Pediatric H3 K27M Gliomas
NCT03416530
terminatedphase_2
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
NCT03485729
terminatedphase_2
Oral ONC201 in Adult Recurrent Glioblastoma
NCT02525692
Clinical Trials (5)
Showing 5 of 5 trials
NCT05580562Phase 3
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT03295396Phase 2
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
NCT03416530Phase 1
ONC201 in Pediatric H3 K27M Gliomas
NCT03485729Phase 2
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
NCT02525692Phase 2
Oral ONC201 in Adult Recurrent Glioblastoma
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5